. 2021 Dec 5;14(11):100610. doi: 10.1016/j.waojou.2021.100610

Table 3.

Recommended dose and treatment duration for patients with other allergic comorbidities

CSU with other allergic comorbidities	Recommended dose	Recommended treatment duration
CSU with CRSwNP⁷⁶^,⁷⁸	300 mg or higher dose according to asthma dosing table	At least 6 months, then the dose and treatment duration should be adjusted according to clinical needs
CSU with food allergy⁷⁷∗	300 mg or higher dose according to asthma dosing table	For food allergy: evaluate response after 16 or 20 weeks treatment, continue to 24 weeks if good response
CSU with ABPA⁷⁹^,⁸⁰∗	375 mg/2 weeks	At least 6 months, then the dose and treatment duration should be adjusted according to clinical needs
CSU with allergic asthma⁸¹	300 mg or higher dose according to asthma dosing table	Evaluate response after 16 weeks, At least 12 months, then the dose and treatment duration should be adjusted according to clinical needs
CSU with allergic rhinitis⁸¹	300 mg or higher dose according to asthma dosing table	Evaluate response after 16 weeks, re-evaluate after 1-year treatment if good response
CSU with AD⁸²∗	150–450mg/2 week	Refer to Fig. 1 for stopping strategy

∗Limited clinical evidence, it is recommended to base treatment decision on the clinical situation. In cases where both the dose strength and frequency differ, result in the higher monthly dose is recommended.

CSU: chronic spontaneous urticaria; CRSwNP: chronic rhinosinusitis with nasal polyps; ABPA: allergic bronchopulmonary aspergillosis; AD: atopic dermatitis